PayPal Holdings, Inc. (PYPL) saw its value increase by 2.15% as the stock gained $0.86 to finish the day at a closing price of $40.88. The stock was higher in trading and has fluctuated between $32.01-$44.52 per share for the past year. The shares, which traded within a range of $39.92 to $40.99 during the day, are down by -0.97% in the past three months and up by 7.3% over the past six months. It is currently trading 0.19% above its 20 day moving average and 1.75% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $46.83 a share over the next twelve months. The current relative strength index (RSI) reading is 55.32.The technical indicator lead us to believe there will be no major movement any time soon, hold.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.
Fifth Third Bancorp (FITB) shares were down in last trading by -2.27% to $25.89. It experienced higher than average volume on day. The stock decreased in value by almost -1.33% over the past week and fell -3.25% in the past month. It is currently trading -2.82% below its 50 day moving average and 21.92% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -6.67% decrease in value from its one year high of $27.88. The RSI indicator value of 42.33, lead us to believe that it is a hold for now.
Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors. The Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers. The Branch Banking segment provides deposit and loan products to individuals and small businesses. This segment offers checking and savings accounts, home equity loans and lines of credit, credit cards, and loans for automobiles and personal financing needs. The Consumer Lending segment engages in direct lending activities that include origination, retention, and servicing of residential mortgage and home equity loans or lines of credit; and indirect lending activities, including loans to consumers through correspondent lenders and automobile dealers. The Investment Advisors segment provides various investment alternatives for individuals, companies, and not-for-profit organizations. It offers retail brokerage services to individual clients; and broker dealer services to the institutional marketplace. This segment also provides asset management services; holistic strategies to affluent clients in wealth planning, investing, insurance, and wealth protection; and advisory services for institutional clients comprising states and municipalities. As of December 31, 2015, the company operated 1,254 full-service banking centers, including 95 Bank Mart locations, as well as 2,593 automated teller machines in 12 states throughout the Midwestern and Southeastern regions of the United States. Fifth Third Bancorp was founded in 1862 and is headquartered in Cincinnati, Ohio.
Boston Scientific Corporation (BSX) traded within a range of $25.15 to $25.32 after opening the day at $25.2. The company has seen its stock increase in value by 16.69% so far this year. The stock was up close to 0.04% on light volume in last trading session and closed at $25.24 per share. After the recent gain, the stock is currently holding -0.55% below its 52 week high of $25.38 and 61.07% above its 12-month low of $16.4. The shares are up by over 14.52% in the last three months, and the RSI indicator value of 80.64 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.